The ranking is based on a survey of leaders from the biotechnology, biopharmaceutical, pharmaceutical and related industries. In the annual survey, respondents were asked to rate companies on 23 characteristics. Survey responses were then analyzed by The Brighton Consulting Group, which used a mathematical process to assign a unique score to rate each company's employer reputation. Each company received a ranking, for example, on the basis of whether it treats its employees with respect, whether its work-culture values align with employees' personal values and other factors.
As a privately held company, Boehringer Ingelheim is able to take a long-term approach to research and development (R&D), which enables the Company to create a stable and consistent environment for investing in the development of novel medicines to address unmet needs. This vision is supported by significant levels of investment in human pharmaceutical R&D, including a planned investment of around 11 billion euros in international research and development over the next five years.
For the feature story on the survey, along with individual company rankings, visit sciencecareers.org/TopEmployers2016.
This recognition follows the recent news that Boehringer Ingelheim was named to the Working Mother magazine 100 Best Companies List for the fifth consecutive year.
About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with 145 affiliates and more than 47,000 employees. Since its founding in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel treatments for human and veterinary medicine.
Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Our employees create and engage in programs that strengthen our communities. To learn more about how we make more health for more people, visit our Corporate Social Responsibility Report.
In 2015, Boehringer Ingelheim achieved net sales of about $15.8 billion (14.8 billion euros). R&D expenditure corresponds to 20.3 percent of its net sales.
For more information please visit www.us.boehringer-ingelheim.com, or follow us on Twitter @BoehringerUS.
Name: Erin Crew
Phone: (203) 798-5564
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/boehringer-ingelheim-named-one-of-science-magazines-top-employers-for-the-twelfth-consecutive-year-300352790.html
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.